In Part 2 of our conversation, Scott Ohanesian, QuickSTAT’s senior VP of Commercial Operations, and Mike Sweeney, QuickSTAT's Global Head of Strategy for CGT and Direct to Patient Products discuss the various challenges around the logistics of Cell & Gene Therapy – what to look out for and the importance of being prepared.

We also look forward and consider not only the sector’s growth, but what that growth will mean for supply chain logistics. To understand that future, however, we began by asking Mike Sweeney to provide the context of when gene therapy began – and, importantly, how we got from there to here?

For more information on clinical trial logistics, visit our website at quickstat.com.